Impax Laboratories (IPXL) announces that it's licensed the U.S. commercialization rights for...

|By:, SA News Editor

Impax Laboratories (IPXL) announces that it's licensed the U.S. commercialization rights for Zomig from AstaZeneca (AZN). The firm says the deal will be immediately accretive to EPS in 2012, and now sees gross margins of 60% as a percentage of total revenue for the year.